Publications by authors named "Qiao-Yan Zhu"
Long-term survival varies among hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer patients and is seriously impaired by metastasis. Chromosomal instability (CIN) was one of the key drivers of breast cancer metastasis. Here we evaluate CIN and 10-year invasive disease-free survival (iDFS) and overall survival (OS) in HR+/HER2-- breast cancer.
View Article and Find Full Text PDFArticle Synopsis
- This study investigates the role of mutations in breast cancer patients in China, particularly focusing on hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative cases.
- Out of 629 women diagnosed with breast cancer, 78 (12.4%) had mutations, which were linked to lower average age at diagnosis and higher rates of lymph node positivity compared to non-mutation cases.
- Findings indicate that while mutation breast cancers had some adverse characteristics, such as a higher prevalence of familial breast and ovarian cancer history, mutations did not significantly impact invasive disease-free survival or distant relapse-free survival.
Background: The clinical outcomes of chemotherapy (CT) for the treatment of metastatic triple-negative (TN) and hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) have proven to be disappointing. The phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway, a tumor-promoting signaling cascade frequently mutated in breast cancer (BC), has been implicated in chemoresistance. In this study, our objective is to investigate the efficacy and safety of combining everolimus with chemotherapy in mBC patients exhibiting mutations in the PI3K/AKT/mTOR pathway.
View Article and Find Full Text PDFA comprehensive analysis of Fanconi anemia genes in Chinese patients with high-risk hereditary breast cancer.
J Cancer Res Clin Oncol
November 2023
Article Synopsis
- - The study examined the role of 16 Fanconi anemia (FA) genes in breast cancer (BC) among 1481 high-risk hereditary BC patients in China, identifying 38 patients with mutations in these genes, mainly FANCA.
- - Findings indicated that FA gene mutation carriers had worse clinicopathological features, including higher tumor sizes and lower survival rates compared to non-carriers, along with significant differences in lymph node status.
- - The research suggests that specific FA gene mutations may contribute to breast cancer risk, and further exploration is warranted to better understand their implications in various populations.
is a tumor suppressor gene as well as a disease-causing gene for autosomal dominant disorder tuberous sclerosis complex (TSC). Research has found that some tumor tissues have lower TSC2 expression levels than normal tissues. Furthermore, low expression of TSC2 is associated with poor prognosis in breast cancer.
View Article and Find Full Text PDF